Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Boehringer Ingelheim To Develop Cancer Drugs Aimed At Degrading Proteins

XTALKS VITALS NEWS

FDA

“We are very excited to partner with Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies,” said Dr. Alessio Ciulli, Associate Professor of Chemical and Structural Biology at the University of Dundee.

Tweetables from this article:

Tweet: Boehringer Ingelheim will develop a new class of proteolytic #cancer drugs http://ctt.ec/0y_j4+Boehringer Ingelheim will develop a new class of proteolytic cancer drugs.

Tweet: PROTACs have the potential to play a role in the treatment of cancer as well as other diseases http://ctt.ec/l3c84+PROTACs have the potential to play a role in the treatment of cancer as well as other diseases.

Share this!

July 15, 2016 | by Sarah Massey, M.Sc.

In collaboration with the researchers at the University of Dundee in Scotland, pharmaceutical company Boehringer Ingelheim will develop a new class of proteolytic cancer drugs. The drugs – named proteolysis targeting chimeric molecules (PROTACs) – will be designed to use the cell’s own housekeeping system to degrade proteins that could lead to the development of diseases like cancer.

By simultaneously binding to an ubiquitin ligase and a protein, PROTACs can trigger a cellular process capable of breaking-down the target molecule. As researchers have used RNAi screens to identify potential disease-causing proteins – including the bromodomain and extraterminal (BET) domain family – PROTACs have the potential to play a role in the treatment of cancer as well as other diseases.

“We believe our approach has the potential to fundamentally transform how we tackle protein targets to fight disease,” said Dr. Alessio Ciulli, Associate Professor of Chemical and Structural Biology at the University of Dundee. “We are very excited to partner with Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies.”



The University of Dundee is a leader in PROTAC research, and teaming up with Boehringer Ingelheim could push the technology from experimental to practical. Despite the platform’s past issues, the team could make some major headway on PROTAC development.

Research into the protein-degrading molecules began 16 years ago, but many researchers have found it challenging to identify small molecule drug candidates with sufficient binding affinity and specificity for ubiquitin ligases.

According to recent research published by Ciulli’s team, the researchers have identified a drug candidate capable of targeting a protein – named BRD4 – which has been implicated in acute myeloid leukemia, ovarian carcinoma and chronic obstructive pulmonary disease. “This is a prime example of an industry-academia collaboration to establish a disruptive new approach to drug discovery, initially developed in academia, and to enable its translation all the way to benefit patients,” said Ciulli.


Keywords: Cancer, Drug Development, Pharmaceuticals


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News


PTC to Acquire Marathon’s Recently Approved Duchenne Muscular Dystrophy Drug

March 17, 2017 - Amid a drug pricing controversy, PTC Therapeutics has agreed to buy Marathon Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug, Emflaza.

Featured In: Pharmaceutical News


Memphis Meats Produces World’s First Poultry from Animal Cells

March 17, 2017 - Silicon Valley-based food manufacturing company, Memphis Meats, has produced the world’s first “clean poultry” by growing chicken and duck cells outside the animals.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.